Suppr超能文献

多中心心脏血流动力学评估 LOT-CRT 策略:联合左束支起搏和冠状静脉起搏增强心脏再同步化治疗的最佳时机是什么?:CSPOT 研究的主要结果。

Multicenter Hemodynamic Assessment of the LOT-CRT Strategy: When Does Combining Left Bundle Branch Pacing and Coronary Venous Pacing Enhance Resynchronization?: Primary Results of the CSPOT Study.

机构信息

First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University, Medical College, Krakow, Poland (M.J.).

Wiltshire Cardiac Center, Great Western Hospital, Swindon, United Kingdom (P.F., B.C.).

出版信息

Circ Arrhythm Electrophysiol. 2024 Nov;17(11):e013059. doi: 10.1161/CIRCEP.124.013059. Epub 2024 Oct 23.

Abstract

BACKGROUND

Left bundle branch area pacing (LBBAP) may be an alternative to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT). We sought to compare the acute hemodynamic and ECG effects of LBBAP, BVP, and left bundle-optimized therapy CRT (LOT-CRT) in CRT candidates with advanced conduction disease.

METHODS

In this multicenter study, 48 patients with either nonspecific interventricular conduction delay (n=29) or left bundle branch block (n=19) underwent acute hemodynamic testing to determine the change in left ventricular pressure maximal first derivative (LV d/d) from baseline atrial pacing to BVP, LBBAP, or LOT-CRT.

RESULTS

Atrioventricular-optimized increases in LV d/d for LOT-CRT (mean, 25.8% [95% CI, 20.9%-30.7%]) and BVP (26.4% [95% CI, 20.2%-32.6%]) were greater than unipolar LBBAP (19.3% [95% CI, 15.0%-23.7%]) or bipolar LBBAP (16.4% [95% CI, 12.7%-20.0%]; ≤0.005). QRS shortening was greater in LOT-CRT (29.5 [95% CI, 23.4-35.6] ms) than unipolar LBBAP (11.9 [95% CI, 6.1-17.7] ms), bipolar LBBAP (11.7 ms [95% CI, 6.4-17.0]), or BVP (18.5 [95% CI, 11.0-25.9] ms), all ≤0.005. Compared with patients with left bundle branch block, patients with interventricular conduction delay experienced less QRS reduction (=0.026) but similar improvements in LV d/d (=0.29). Bipolar LBBAP caused anodal capture in 54% of patients and resulted in less LV d/d improvement than unipolar LBBAP (18.6% versus 23.7%; <0.001). Subclassification of LBBAP capture (European Heart Rhythm Association criteria) indicated LBBAP or LV septal pacing in 27 patients (56%) and deep septal pacing in 21 patients (44%). The hemodynamic benefit of adding left ventricular coronary vein pacing to LBBAP depended on baseline QRS duration (=0.031) and success of LBBAP (<0.004): LOT-CRT provided 14.5% (5.0%-24.1%) greater LV d/d improvement and 20.8 (12.8-28.8) ms greater QRS shortening than LBBAP in subjects with QRS ≥171 ms and deep septal pacing capture type.

CONCLUSIONS

In a CRT cohort with advanced conduction disease, LOT-CRT and BVP provided greater acute hemodynamic benefit than LBBAP. Subjects with wider QRS or deep septal pacing are more likely to benefit from the addition of a left ventricular coronary vein lead to implement LOT-CRT.

REGISTRATION

URL: https://www.clinicaltrials.gov; Unique identifier: NCT04905290.

摘要

背景

左束支区域起搏(LBBAP)可能是心脏再同步治疗(CRT)的双心室起搏(BVP)的替代方案。我们旨在比较在伴有高级传导疾病的 CRT 候选者中,LBBAP、BVP 和左束支优化治疗 CRT(LOT-CRT)的急性血液动力学和心电图影响。

方法

在这项多中心研究中,29 名患者有非特异性室内传导延迟,19 名患者有左束支传导阻滞,他们接受了急性血液动力学测试,以确定从基础的心房起搏到 BVP、LBBAP 或 LOT-CRT 的左心室压力最大一阶导数(LV d/d)的变化。

结果

对于 LOT-CRT(平均,25.8%[95%置信区间,20.9%-30.7%])和 BVP(26.4%[95%置信区间,20.2%-32.6%]),房室优化增加的 LV d/d 大于单极 LBBAP(19.3%[95%置信区间,15.0%-23.7%])或双极 LBBAP(16.4%[95%置信区间,12.7%-20.0%];≤0.005)。与 LOT-CRT(29.5 [95% CI, 23.4-35.6] ms)相比,LBBAP(11.9 [95% CI, 6.1-17.7] ms)、双极 LBBAP(11.7 [95% CI, 6.4-17.0] ms)或 BVP(18.5 [95% CI, 11.0-25.9] ms)的 QRS 缩短更大,所有均≤0.005。与左束支传导阻滞患者相比,伴有室内传导延迟的患者 QRS 减少幅度较小(=0.026),但 LV d/d 改善程度相似(=0.29)。双极 LBBAP 在 54%的患者中引起阳极捕获,与单极 LBBAP(18.6%比 23.7%;<0.001)相比,LV d/d 的改善程度较低。LBBAP 捕获的亚分类(欧洲心脏节律协会标准)表明,27 名患者(56%)为 LBBAP 或左心室间隔起搏,21 名患者(44%)为深间隔起搏。将左心室冠状静脉起搏加入 LBBAP 的益处取决于基线 QRS 持续时间(=0.031)和 LBBAP 的成功(<0.004):在 QRS≥171 ms 且具有深间隔起搏捕获类型的患者中,与 LBBAP 相比,LOT-CRT 可提供 14.5%(5.0%-24.1%)更大的 LV d/d 改善和 20.8(12.8-28.8)ms 的更大 QRS 缩短。

结论

在伴有高级传导疾病的 CRT 队列中,LOT-CRT 和 BVP 比 LBBAP 提供了更大的急性血液动力学益处。具有较宽 QRS 波或深间隔起搏的患者更有可能受益于添加左心室冠状静脉导线来实施 LOT-CRT。

登记

网址:https://www.clinicaltrials.gov;独特标识符:NCT04905290。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3d9/11575906/a5c6d0f30105/hae-17-e013059-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验